COEXISTING AUTOIMMUNE HAEMOLYSIS AND PNEUMOCYSTIS JIROVECII PNEUMONIA IN AN ELDERLY COPD PATIENT: A CASE REPORT
Main Article Content
Keywords
Pneumocystis jirovecii, PCP, Autoimmune haemolytic anaemia, chronic obstructive pulmonary disease, Giemsa and toluidine blue O and Trimethoprim–sulfamethoxazole
Abstract
Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection, mostly seen in individuals with overt immunosuppression, such as those living with HIV/AIDS. However, recent trends show increasing incidence in individuals without classical risk factors, prompting the need for broader clinical awareness. We present a complex and ultimately fatal case of PCP in an elderly man with chronic obstructive pulmonary disease (COPD), whose clinical course was complicated by newly diagnosed autoimmune haemolytic anaemia (AIHA).The patient, a 72-year-old man, arrived with progressively worsening breathlessness, fatigue, and pallor, initially attributed to a COPD exacerbation. He had no history of immunosuppressive therapy, HIV, or known immunodeficiency. However, laboratory investigations revealed severe anaemia, and a positive Direct Coombs Test confirmed AIHA. A chest CT scan raised concern for a complex pulmonary infection in an already compromised lung with findings not typical of PCP alone, but possibly exacerbated by the underlying COPD and emerging immune dysfunction from AIHA. Ultimately, microscopic examination of induced sputum stained with Giemsa and toluidine blue O confirmed P. jirovecii infection. Although, trimethoprim-sulfamethoxazole and corticosteroids were promptly initiated, the patient succumbed to progressive respiratory failure within six days. This case underscores the importance of considering PCP in non-HIV patients, particularly those with chronic lung disease and immune dysfunction. Although rare, AIHA in COPD can further weaken immune defences, heightening the risk of severe infections. The diagnostic challenge posed by clinical overlap with bacterial pneumonia and tuberculosis in non-HIV PCP underscores the need for early empirical treatment, prompt recognition, and targeted therapy to improve outcomes.
References
2. Ricciardi A, Gentilotti E, Coppola L, Maffongelli G, Cerva C, Malagnino V, Mari A, Di Veroli A, Berrilli F, Apice F, Toschi N, Di Cave D, Parisi SG, Andreoni M, Sarmati L. Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS One2017;12:e0176881. https://doi.org/10.1371/journal.pone.0176881.
3. Alanio A, Bretagne S. Pneumocystis jirovecii detection in asymptomatic patients: What does its natural history tell us? F1000Res2017;6:739. https://doi.org/10.12688/f1000research.10619.1.
4. Prosty C, Katergi K, Sorin M, Rjeily MB, Butler-Laporte G, McDonald EG, Lee TC. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials. Clin Microbiol Infect2024;30:866-876. https://doi.org/10.1016/j.cmi.2024.03.037.
5. Mundo W, Morales-Shnaider L, Tewahade S, Wagner E, Archuleta S, Bandali M, Chadalawada S, Johnson SC, Franco-Paredes C, Shapiro L, Henao-Martínez AF. Lower mortality associated with adjuvant corticosteroid therapy in non-HIV-infected patients pith Pneumocystis jirovecii pneumonia: A single-institution retrospective US cohort study. Open Forum Infect Dis2020;7:ofaa354. https://doi.org/10.1093/ofid/ofaa354.
6. McMullan B, Kim HY, Alastruey-Izquierdo A, Tacconelli E, Dao A, Oladele R, Tanti D, Govender NP, Shin JH, Heim J, Ford NP, Huttner B, Galas M, Nahrgang SA, Gigante V, Sati H, Alffenaar JW, Morrissey CO, Beardsley J. Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list. Med Mycol2024;62:myae038. https://doi.org/10.1093/mmy/myae038.
7. Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L, Groll AH. Pneumocystis jirovecii disease: Basis for the revised EORTC/MSGERC invasive fungal disease definitions in individuals without Human Immunodeficiency Virus. Clin Infect Dis 2021;72(Suppl 2):S114-S120. https://doi.org/10.1093/cid/ciaa1805.
8. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, Huang L, Norris KA. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004;170:408-413. https://doi.org/10.1164/rccm.200401-094OC.
9. Sivam S, Sciurba FC, Lucht LA, Zhang Y, Duncan SR, Norris KA, Morris A. Distribution of Pneumocystis jirovecii in lungs from colonized COPD patients. DiagnMicrobiol Infect Dis 2011;71:24-28. https://doi.org/10.1016/j.diagmicrobio.2011.05.008.
10. Coronado K, Herrada C, Rojas DA.Role of the fungus Pneumocystis in IL1β pathway activation and airways collagen deposition in elastase-induced COPD animals. Int J Mol Sci 2024;25:3150. https://doi.org/10.3390/ijms25063150.
11. Rabacal W, Rayens E, Norris K. Pneumocystis as a co-factor in pulmonary diseases. OBM Genet 2018;2:57. https://doi.org/10.21926/obm.genet.1804057.
12. Morris A, Sciurba FC, Norris KA. Pneumocystis: A novel pathogen in chronic obstructive pulmonary disease? COPD 2008;5:43-51. https://doi.org/10.1080/15412550701817656.
13. Rojas DA, Iturra PA, Méndez A, Ponce CA, Bustamante R, Gallo M, Bórquez P, Vargas SL.Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection. Sci Rep 2019;9:2078. https://doi.org/10.1038/s41598-019-39079-4.
14. Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest 2020;158:2323-2332. https://doi.org/10.1016/j.chest.2020.05.558.
15. Mouren D, Goyard C, Catherinot E, Givel C, Chabrol A, Tcherakian C, Longchampt E, Vargaftig J, Farfour E, Legal A, Couderc LJ, Salvator H.COVID-19 and Pneumocystis jirovecii pneumonia: Back to the basics. Respir Med Res 2021;79:100814. https://doi.org/10.1016/j.resmer.2021.100814.
16. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Cordonnier C, Maertens J, Bretagne S; 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J AntimicrobChemother2016;71:2386-2396. https://doi.org/10.1093/jac/dkw156.
17. Rouhi F, Erami M, Rastgufar S, Jahani M, Aboutalebian S, Soltani S, Fakhim H, Mirhendi H.Quantitative real time PCR for distinction between Pneumocystis jirovecii infection/colonization in hospitalized patients. Front Cell Infect Microbiol2024;14:1426200. https://doi.org/10.3389/fcimb.2024.1426200.
18. Jaramillo Cartagena A, Asowata OE, Ng D, Babady NE. An overview of the laboratory diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol 2025;63:e0036124. https://doi.org/10.1128/jcm.00361-24.
19. Robin C, Cordonnier C, Tridello G, Knelange N, Xhaard A, Chantepie S, Tanguy-Schmidt A, Schouten HC, Yeshurun M, Rocha V, Srour M, Kröger N, Ledoux MP, Dalgaard J, Thiebaut A, Giardino S, Calore E, Zuckerman T, Groll AH, Raida L, Avcin S, Vicent MG, Kaare A, Drozd-Sokolowska J, Turlure P, Bretagne S, Mikulska M, Camara R, Cesaro S, Styczynski J.Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the infectious diseases working party of the European society for blood and marrow transplantation. Transplant Cell Ther2024;30:235.e1-235.e10. https://doi.org/10.1016/j.jtct.2023.11.017.
20. Xue T, Ma Z, Liu F, Du W, He L, Wang J, An C. Pneumocystis jirovecii colonization and its association with pulmonary diseases: a multicenter study based on a modified loop-mediated isothermal amplification assay. BMC PulmMed .2020;20:70. https://doi.org/10.1186/s12890-020-1111-4.
21. Shaykhiev R, Crystal RG. 2013. Innate immunity, and chronic obstructive pulmonary disease: A mini-review. Gerontology 59:481–489. https://doi.org/10.1159/000354173.
22. Plascencia-Cruz M, Plascencia-Hernández A, De Armas-Rodríguez Y, Cervantes-Guevara G, Cervantes-Cardona GA, Ramírez-Ochoa S, González-Ojeda A, Fuentes-Orozco C, Hernández-Mora FJ, González-Valencia CM, Pérez de Acha-Chávez A, Cervantes-Pérez E. Pneumocystis jirovecii colonization in Mexican patients with chronic obstructive pulmonary disease. Trop Med Infect Dis 2023;8:137. https://doi.org/10.3390/tropicalmed8030137.
23. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008;197:10–17. https://doi.org/10.1086/523814.
24. Calderón EJ, Rivero L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, Muñoz-Lobato F, Varela JM, Medrano FJ, Horra Cde L. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 2007;45:e17-9. https://doi.org/10.1086/518989.
25. Loriamini M, Cserti-Gazdewich C, Branch DR. Autoimmune hemolyticanemias: Classifications, pathophysiology, diagnoses and management. Int J Mol Sci 2024;25:4296https://doi.org/10.3390/ijms25084296.
26. Ibrahim A, Chattaraj A, Iqbal Q, Anjum A, Rehman MEU, Aijaz Z, Nasir F, Ansar S, Zangeneh TT, Iftikhar A. Pneumocystis jirovecii pneumonia: A review of management in human immune deficiency virus (HIV) and non-HIV immunocompromised patients. Avicenna J Med 2023;13:23–34. https://doi.org/10.1055/s-0043-1764375.
27. Frieder J, Mouabbi JA, Zein R, Hadid T.Autoimmune hemolyticanemia associated with trimethoprim-sulfamethoxazole use. Am J Health Syst Pharm 2017;74:894–897 https://doi.org/10.2146/ajhp160203.
28. Stone RM, Haidar CE, Kornegay NM, Barker PJ, Karol SE, Wolf J, Hankins JS, Relling MV, Crews KR.Sulfamethoxazole-Trimethoprim prophylaxis in pediatric oncology patients with Ggucose-6-phosphate dehydrogenase deficiency. Pediatr Infect Dis J.2024;10.1097/INF.0000000000004515.https://doi.org/10.1097/INF.0000000000004515.
29. Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, Formea CM, Elchynski AL, Oshikoya KA, McLeod HL, Haidar CE, Whirl-Carrillo M, Klein TE, Caudle KE, Relling MV.Expanded clinical pharmacogenetics implementation consortium guideline for medication use in the context of G6PD genotype. Clin PharmacolTher2023;113:973-985. https://doi.org/10.1002/cpt.2735.
30. Kato H, Hagihara M, Asai N, Umemura T, Shibata Y, Hirai J, Yamagishi Y, Iwamoto T, Mikamo H. Efficacy of Trimethoprim-Sulfamethoxazole in combination with an echinocandin as a first-line treatment option for Pneumocystis pneumonia: A systematic review and meta-analysis. Antibiotics (Basel) 2022;11:719. https://doi.org/10.3390/antibiotics11060719.
31. Cushion MT, Ashbaugh A. The long-acting echinocandin, rezafungin, prevents Pneumocystis pneumonia and eliminates Pneumocystis from the lungs in prophylaxis and murine treatment models. J Fungi 2021;7:747. https://doi.org/10.3390/jof7090747.
32. Hsu JM, Hass A, Gingras MA, Chong J, Costiniuk C, Ezer N, Fraser RS, McDonald EG, Lee TC. Radiographic features in investigated for Pneumocystis jirovecii pneumonia: a nested case-control study. BMC Infect Dis 2020;20:492. https://doi.org/10.1186/s12879-020-05217-x
33. Truong J, Ashurst JV. Pneumocystis jirovecii pneumonia. StatPearls. Treasure Island, FL, USA, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482370/ [Updated 2023 Jan 21].
34. P. Lewis White et al. Therapy and Management of Pneumocystis jirovecii Infection. J. Fungi 2018, 4(4), 127.
35. Qiuyue Feng and Zhaohui Tong et al. Clinical Characteristics and Prognostic Predictors of Pneumocystis Jirovecii Pneumonia in Patients with and without Chronic Pulmonary Disease: A Retrospective Cohort Study. Infect Drug Resist. 2024 May 30;17:2169–2182.
36. Qian Yang et al. Case Report: Severe Pneumocystis jirovecii pneumonia following zuberitamab treatment in autoimmune hemolytic anemia. Front Immunol . 2025 Mar 11:16:1546571.